BHVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Biohaven Ltd (BHVN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a bearish technical trend, lacks significant positive trading signals, and has mixed analyst ratings with a cautious outlook on its pipeline. While insider buying is a positive indicator, the company's financial performance and recent setbacks in clinical trials suggest a wait-and-see approach is more prudent.
The technical indicators for BHVN are bearish. The MACD histogram is negative and contracting, RSI is neutral at 41.788, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 11.776, with key support at 10.833 and resistance at 12.72.
Insider buying has increased significantly by 3226.99% over the last month, indicating confidence from company insiders.
Analysts from Goldman Sachs and RBC Capital have recently issued positive ratings with price targets of $23 and $22, respectively, citing the potential of BHV-1400 in IgA nephropathy and an improved financial position.
The stock has faced multiple research and development setbacks, including the failure of BHV-7000 in a Phase 2 study for major depressive disorder.
Analysts like H.C. Wainwright and UBS have downgraded the stock, citing limited confidence in the pipeline and competitive disadvantages.
The company's financials remain weak, with negative net income and EPS, and no revenue growth.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$173.44M (up 8.20% YoY), and a drop in EPS to -1.64 (-3.53% YoY). Gross margin remains at 0, reflecting the company's pre-revenue stage and high operational costs.
Analyst ratings are mixed. Positive ratings from Goldman Sachs and RBC Capital highlight potential in the company's pipeline and financial improvements, with price targets of $23 and $22. However, H.C. Wainwright and UBS downgraded the stock to Neutral, citing setbacks in clinical trials and competitive disadvantages. The consensus reflects a cautious optimism with significant risks.
